ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2117

Frailty Is Associated with Mortality in Veterans with Rheumatoid Arthritis

Sayuli Bhide1, Punyasha Roul2, Namrata Singh3, Grant Cannon4, Gary Kunkel5, Ted R Mikuls6, Bryant England2, Dolores Shoback7, Patti Katz8, Jose Garcia9, Ariela Orkaby10, Joshua Baker11 and K Wysham12, 1University of Washington, Seattle, WA, 2University of Nebraska Medical Center, Omaha, NE, 3University of Washington, Bellevue, WA, 4University of Utah and Salt Lake City VA, Salt Lake City, UT, 5University of Utah, Salt Lake City, UT, 6Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, 7San Francisco VA Medical Center, San Francisco, CA, 8University of California San Francisco, San Rafael, CA, 9VA Puget Sound Healthcare System, Seattle, WA, 10Veterans Affairs Boston Healthcare System & Brigham and Women’s Hospital, Harvard Medical School, Boston, MA; VA Geriatric Research Education and Clinical Center, Boston, MA, 11University of Pennsylvania, Philadelphia, PA, 12VA Puget Sound/University of Washington, Seattle, WA

Meeting: ACR Convergence 2023

Keywords: Aging, Disease Activity, Mortality, rheumatoid arthritis, risk factors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2095–2140) RA – Diagnosis, Manifestations, and Outcomes Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Frailty is established as an important predictor of mortality in the general population.1Rheumatoid arthritis (RA) is associated with higher rates of frailty than the general population,2 yet how frailty impacts important outcomes in RA, such as mortality, is less well understood. We sought to evaluate the relationship between frailty and mortality in a cohort of Veterans with RA.

Methods: Data were obtained from the Veterans Affairs Rheumatoid Arthritis (VARA) Registry from 1/2003 through 12/2021. The VA Frailty Index(VA-FI) is a validated deficit accumulation index based on 31 health deficits mapped from >6000 diagnostic codes found in administrative claims and electronic health records of Veterans. The VA-FI was calculated for each participant at baseline using diagnostic codes with a 3-year look-back period. The VA-FI scores were categorized as robust, pre-frail and frail based on established cutoffs. Death data were obtained from the VA Corporate Data Warehouse vital statistics records. Cox proportional hazard regression models were used to evaluate the relationship between baseline frailty and mortality controlling for baseline age, sex, race, body mass index, anti-cyclic citrullinated peptide (CCP) status, RA disease duration, smoking status, rheumatic disease comorbidity index, use of prednisone, conventional synthetic disease modifying anti-rheumatic drugs (DMARDs) and biologic DMARDs.

Results: 3,007 Veterans were studied with a mean age of 64.4±11.1 years and 85% were male (Table 1). Over 16,515 person-years of follow-up, 43% (N=1,293) Veterans died. Those who died were older (68.9 vs. 61.0 years), more likely to be male (95% vs. 82%) and had higher rates of high disease activity (21% vs 12%, respectively). Those who died also had higher prevalence of baseline pre-frailty and frailty compared to those who did not die (40% vs. 34% and 38 vs. 30%, respectively). In multivariable models, pre-frailty and frailty were independently associated with a higher risk of death(HR 1.43 [95%CI 1.22-1.69] and 1.90 [95%CI 1.56-2.30], respectively) (Table 2).

Conclusion: Higher baseline frailty is independently associated with an increased risk of death in Veterans with RA. The VA-FI may serve as a tool to aid in early recognition of frailty in people with RA. Further research is necessary regarding the applicability of these findings in informing prognostication and RA disease interventions in vulnerable adults.

References
Orkaby et al. The Burden of Frailty Among U.S. Veterans and Its Association With Mortality, 2002-2012. J Gerontol A Biol Sci Med Sci 2019, 74 (8), 1257–1264.
Gao et al. Frailty in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Joint Bone Spine 2022, 89 (4), 105343.

Supporting image 1

Supporting image 2


Disclosures: S. Bhide: None; P. Roul: None; N. Singh: None; G. Cannon: None; G. Kunkel: None; T. Mikuls: Elsevier, 9, Horizon Therapeutics, 2, 5, Pfizer, 2, Sanofi, 2, UCB Pharma, 2, Wolters Kluwer Health (UpToDate), 9; B. England: Boehringer-Ingelheim, 2, 5; D. Shoback: None; P. Katz: None; J. Garcia: None; A. Orkaby: Anthos therapeutics, 2; J. Baker: Bristol-Myers Squibb(BMS), 2, Burns-White, LLC, 2, CorEvitas, LLC, 2, Pfizer, 2; K. Wysham: None.

To cite this abstract in AMA style:

Bhide S, Roul P, Singh N, Cannon G, Kunkel G, Mikuls T, England B, Shoback D, Katz P, Garcia J, Orkaby A, Baker J, Wysham K. Frailty Is Associated with Mortality in Veterans with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/frailty-is-associated-with-mortality-in-veterans-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/frailty-is-associated-with-mortality-in-veterans-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology